This phase I/II immunotherapy trial is using a new drug (BMS-986205) in combination with Nivolumab and Ipilimumab for the treatment of cancers that are advanced or have spread.
This trial is treating patients with advanced cancers (excluding blood cancer).
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Bristol-Myers Squibb (BMS)
The purpose of the study is to determine safety, tolerability, pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab [an anti-Programmed cell Death-1(anti-PD1) antibody] in patients with advanced cancers.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More